Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology

Core Insights - Recordati S.p.A. has launched the 12th edition of the Arrigo Recordati Prize, focusing on advancing research in paediatric oncology, particularly in sarcomas, which are significant contributors to cancer-related deaths in children [1][10] Group 1: Prize Details - The 2026 edition of the Arrigo Recordati Prize aims to spotlight and support pioneering research in paediatric oncology, fostering collaboration across disciplines and supporting early-career investigators [3][4] - The winning project will receive a research grant of €250,000, with applications open to young investigators of all nationalities until 31 January 2026 [5][10] Group 2: Research Focus - Advancing understanding of the pathophysiology of paediatric sarcomas is crucial for developing effective and tolerable targeted therapies, with a focus on translational efforts to improve outcomes [2][10] - There has been little innovation in treatment progress for paediatric sarcomas over the past 40 years, highlighting the need for new research initiatives [10] Group 3: Company Background - Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, with operations in approximately 150 countries and over 4,500 employees, dedicated to treating rare diseases [8][7] - The company has been committed to promoting excellence in orphan disease treatment research since 2019, reflecting its dedication to improving public health [7][6]